X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Under the License Agreement, SciClone will be responsible for conducting and funding local clinical development as well as commercialization of Vaborem® (meropenem). To facilitate patients in China, SciClone will conduct local clinical trials and pursue approvals in China.
Lead Product(s): Meropenem,Vaborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Vaborem
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciClone
Deal Size: $113.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2022
Details:
Under the terms of the deal, Hikma will responsible for the registration and commercialization of Orbactiv and Vabomere across its 18 MENA markets. This extends Hikma’s existing partnership with Melinta for their intravenous and oral formulations of Baxdela.
Lead Product(s): Meropenem,Vaborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Vabomere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
